Dabigatran etexilate is a new type of synthetic direct thrombin inhibitor, a prodrug of dabigatran, and a non-peptide thrombin inhibitor. After oral administration and gastrointestinal absorption, it is transformed into dabigatran with direct anticoagulant activity in the body. dabigatran binds to the fibrin-specific binding site of thrombin to prevent fibrinogen from cleavage into fibrin, thereby blocking the final step of the coagulation waterfall network and thrombosis. Dabigatran can dissociate from the fibrin-thrombin conjugate and exert a reversible anticoagulant effect.
